Contract's Annual Value Estimated to Range from $1.5 Million - $3 Million
PRINCETON, N.J., May 6 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a manufacturer and marketer of advanced wound care products, today announced it has signed a new contract to supply private label adhesive bandages to one of the largest medical supply companies in the U.S. Annual revenues under the contract are expected to range between $1.5 to $3.0 million for Derma Sciences. Shipments to the customer will begin in the third quarter of 2009.
"We are delighted to formally announce this new contract, which is a milestone for Derma Sciences and illustrates the promise inherent in our recently acquired First Aid Division (FAD)," said CEO Ed Quilty. "We knew the FAD was a business unit with great potential, once the cost of manufacturing issues were sorted out. The contract illustrates the excellent operational condition of our FAD and is a prime example of why we purchased the division. We believe investors will now begin to see not only the improved costs associated benefits to our bottom line, but also will see accelerated top-line revenue growth as well."
The initial term of the contract is 18 months, with automatic one-year extensions. Either party can terminate the contract upon 90 days notice. Due to the nature of the private label agreement, the name of the medical supply company cannot be made public.
The contract was originally announced during the Company's fourth quarter, year-end results teleconference held on April 1 and sales to the customer were originally estimated to begin in the first quarter of 2010.
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the
Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.
Contact: Derma Sciences, Inc. Edward J. Quilty Chairman and CEO firstname.lastname@example.org (609) 514-4744 Allen & Caron Inc Rudy Barrio (US Investors) email@example.com (212) 691-8087 Brian Kennedy (Media) firstname.lastname@example.org (212) 691-8087
|SOURCE Derma Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved